EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Escape of SARS-CoV-2 Variants KP.1.1, LB.1, and KP.3.3 From Approved Monoclonal Antibodies

Delphine Planas, Isabelle Staropoli, Cyril Planchais, Emilie Yab, Banujaa Jeyarajah, Yannis Rahou, Matthieu Prot, Florence Guivel-Benhassine, Frederic Lemoine, Vincent Enouf, Etienne Simon-Loriere, Hugo Mouquet und 2 weitere

Pathogens and Immunity · 2024

DOI: 10.20411/pai.v10i1.752 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pathogens and Immunity, 2024. Verfasst von Delphine Planas und 13 weiteren Autor:innen. Beteiligte Einrichtung: Virus and Immunity Unit, Institut Pasteur, Université Paris Cité, CNRS UMR3569, Paris, France. Die Arbeit wurde bisher 53-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

First-generation anti-SARS-CoV-2 monoclonal antibodies (mAbs) used for prophylaxis or therapeutic purposes in immunocompromised patients have been withdrawn because of the emergence of resistant Omicron variants. In 2024, 2 novel mAbs, VYD222/Pemivibart and AZD3152/Sipavibart, were approved by health authorities, but their activity against contemporary JN.1 sublineages is poorly characterized.

Methods

We isolated authentic JN.1.1, KP.1.1, LB.1, and KP.3.3 viruses and evaluated their sensitivity to neutralization by these mAbs in 2 target cell lines.

Results

Compared to ancestral strains, VYD222/Pemivibart remained moderately active against JN.1 subvariants, with a strong increase of 50% Inhibitory Concentration (IC50), reaching up to 3 to 15 µg/mL for KP.3.3. AZD3152/Sipavibart neutralized JN.1.1 but lost antiviral efficacy against KP.1.1, LB.1, and KP.3.3.

Conclusions

Our results highlight the need for a close clinical monitoring of VYD222/Pemivibart and raise concerns about the clinical efficacy of AZD3152/Sipavibart.

Schlagwörter

Stichwörter der Autor:innen

PemivibartSARS-CoV-2 variantsSipavibartmonoclonal antibodiesneutralization

Autor:innen und Institutionen

  • Virus and Immunity Unit, Institut Pasteur, Université Paris Cité, CNRS UMR3569, Paris, France.
  • Vaccine Research Institute, Créteil, France.
  • Humoral Immunology Unit, Institut Pasteur, Université Paris Cité, Paris, France.
  • National Reference Center for Respiratory Viruses, Molecular Mechanisms of Multiplication of Pneumoviruses Unit, Institut Pasteur, Université Paris Cité, Paris, France.
  • G5 Evolutionary Genomics of RNA Viruses, Institut Pasteur, Université Paris Cité, Paris, France.
  • Bioinformatics and Biostatistics Hub, Paris, France.

Förderung

  • NIAID NIH HHS

Zitieren

APA

Planas, D., Staropoli, I., Planchais, C., Yab, E., Jeyarajah, B., Rahou, Y., Prot, M., Guivel-Benhassine, F., Lemoine, F., Enouf, V., Simon-Loriere, E., Mouquet, H., Rameix-Welti, M. A., & Schwartz, O. (2024). Escape of SARS-CoV-2 Variants KP.1.1, LB.1, and KP.3.3 From Approved Monoclonal Antibodies. Pathogens and Immunity. https://doi.org/10.20411/pai.v10i1.752

Vancouver

Planas D, Staropoli I, Planchais C, Yab E, Jeyarajah B, Rahou Y, et al. Escape of SARS-CoV-2 Variants KP.1.1, LB.1, and KP.3.3 From Approved Monoclonal Antibodies. Pathogens and Immunity. 2024. doi:10.20411/pai.v10i1.752

BibTeX
@article{Planas2024,
  author = {Planas, Delphine and Staropoli, Isabelle and Planchais, Cyril and Yab, Emilie and Jeyarajah, Banujaa and Rahou, Yannis and Prot, Matthieu and Guivel-Benhassine, Florence and Lemoine, Frederic and Enouf, Vincent and Simon-Loriere, Etienne and Mouquet, Hugo and Rameix-Welti, Marie-Anne and Schwartz, Olivier},
  title = {Escape of SARS-CoV-2 Variants KP.1.1, LB.1, and KP.3.3 From Approved Monoclonal Antibodies},
  journal = {Pathogens and Immunity},
  year = {2024},
  doi = {10.20411/pai.v10i1.752}
}
Kostenlos starten →